Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121939 · ClinicalTrials.gov registry record · Phase 2
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
A Phase 2 study of Neuroendocrine Carcinoma, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 9
- Study locations
NCT01121939 is a Phase 2 study of Neuroendocrine Carcinoma that has completed, run by SCRI Development Innovations. The registered enrollment target is 43 participants, below the 278-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (85% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT01121939, a Phase 2 study of Neuroendocrine Carcinoma, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this Phase II trial will be to define the activity of a VEGF inhibitor bevacizumab, HER1/HER2 inhibitor pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers. In particular, the efficacy of bevacizumab and pertuzumab treatment is of great interest. The primary endpoint of this trial will be response rate. Toxicity and progression-free survival will be obtained and evaluated.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Pertuzumab
- DRUG Sandostatin LAR® Depot
Study Locations (9)
Florida
- Florida Cancer Specialists - Fort Myers
- Florida Hospital Cancer Institute - Orlando
Georgia
- Medical Oncology Associates of Augusta - Augusta
Kentucky
- Baptist Medical Center East - Louisville
Michigan
- Grand Rapids Oncology Program - Grand Rapids
Missouri
- Research Medical Center - Kansas City
New Jersey
- Hematology-Oncology Associates of Northern NJ - Morristown
Ohio
- Oncology Hematology Care, Inc - Cincinnati
Tennessee
- Tennessee Oncology Associates - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121939
The ClinicalTrials.gov registry entry for NCT01121939 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 278-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (85% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01121939 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Florida, Georgia, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01121939 about?
NCT01121939 is a clinical study titled "Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers". The purpose of this Phase II trial will be to define the activity of a VEGF inhibitor bevacizumab, HER1/HER2 inhibitor pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers. In particular, the efficacy of bevacizumab and pertuzumab treatment is of great interest. The prima...
What is the current status of trial NCT01121939?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2010-05. Estimated completion is 2015-08.
What conditions does trial NCT01121939 study?
This clinical trial studies the following conditions: Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT01121939?
The interventions under investigation include: Bevacizumab (DRUG), Pertuzumab (DRUG), Sandostatin LAR® Depot (DRUG).
Who is sponsoring clinical trial NCT01121939?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01121939 being conducted?
This trial has 9 study locations across Florida, Georgia, Kentucky, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.